A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study

Changes in vitamin D metabolites during teriparatide treatment

(2012) Felicia Cosman et al.   BONE

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials

(2012) S.-L. Han et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Safety of osteoanabolic therapy: A decade of experience

(2012) Cristiana Capriani et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial

(2012) David W. Dempster et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis

(2012) Mohammad Hassan Murad et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover

(2011) Mara J Horwitz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis

(2010) Joel S. Finkelstein et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Parathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose

(2010) Mara J. Horwitz et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial

(2008) A. D. Anastasilakis et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE